Table 1 Genes commonly up-regulated throughout epileptogenesis, from the early events post-SE to the onset of recurrent spontaneous seizures.
From: Whole transcriptome analysis of the hippocampus: toward a molecular portrait of epileptogenesis
Accession No. | Fold change | Description | ||
|---|---|---|---|---|
| Â | D3 | D7 | Chronic | Â |
Immune response | ||||
RN.72599 | 5,1 | 12,2 | 7,4 | colony stimulating factor 1 receptor |
RN.16195 | 3,7 | 4,0 | 3,2 | caspase 11 |
RN.14655 | 9,6 | 5,6 | 4,1 | integrin alpha l |
RN.16643 | 4,8 | 4,2 | 3,1 | fc receptor, igg, high affinity i |
RN.2393 | 5,7 | 5,0 | 3,6 | complement component 1, q subcomponent, gamma polypeptide |
RN.6702 | 5,0 | 4,8 | 3,1 | complement component 1, q subcomponent, beta polypeptide |
RN.10089 | 4,7 | 4,2 | 3,8 | cyclin-dependent kinase inhibitor 1a |
RN.48861 | 5,2 | 4,8 | 3,6 | vav 1 oncogene |
RN.10748 | 2,9 | 3,9 | 5,5 | cd4 antigen |
RN.81052 | 2,7 | 4,5 | 4,5 | complement component 4a |
RN.5892 | 5,8 | 6,3 | 5,1 | major histocompatibility complex, class ii, dm beta |
RN.780 | 7,0 | 3,9 | 4,1 | alpha-2-macroglobulin |
RN.38575 | 3,2 | 3,8 | 3,5 | neutrophil cytosolic factor 1 |
RN.100285 | 7,7 | 9,9 | 8,3 | serine (or cysteine) peptidase inhibitor, clade g, member 1 |
RN.92197 | 4,7 | 6,5 | 5,9 | linker for activation of t cells family, member 2 |
RN.3176 | 4,2 | 4,7 | 3,8 | lymphocyte antigen 86 (predicted) |
RN.101608 | 4,9 | 4,2 | 4,5 | lymphocyte specific 1 |
RN.58420 | 3,1 | 2,6 | 2,7 | similar to ikappab-zeta (predicted) |
RN.16670 | 5,9 | 4,2 | 4,5 | basic leucine zipper transcription factor, atf-like (predicted) |
RN.98333 | 4,2 | 4,6 | 4,0 | complement component 2 |
RN.42962 | 4,3 | 6,8 | 6,2 | integrin beta 2 |
RN.105647 | 4,1 | 4,4 | 3,3 | complement component 1, q subcomponent, alpha polypeptide |
RN.37880 | 4,7 | 4,6 | 5,6 | small inducible cytokine a4 |
RN.10330 | 6,7 | 4,8 | 5,9 | cd8 antigen, beta chain |
RN.10139 | 10,9 | 12,8 | 10,1 | chemokine (c-c motif) ligand 3 |
RN.30043 | 4,8 | 5,7 | 4,9 | tumor necrosis factor (ligand) superfamily, member 4 |
RN.3370 | 5,7 | 4,6 | 4,3 | interferon gamma inducible protein 30 |
RN.90166 | 3,4 | 3,7 | 3,2 | protein tyrosine phosphatase, receptor type, c |
RN.33323 | 6,0 | 6,0 | 4,8 | fc receptor, igg, low affinity iib |
Humoral Defense Mechanism | ||||
RN.105647 | 4,1 | 4,4 | 3,3 | complement component 1, q subcomponent, alpha polypeptide |
RN.81052 | 2,7 | 4,5 | 4,5 | complement component 4a |
RN.72599 | 5,1 | 12,2 | 7,4 | colony stimulating factor 1 receptor |
RN.100285 | 7,7 | 9,9 | 8,3 | serine (or cysteine) peptidase inhibitor, clade g, member 1 |
RN.2393 | 5,7 | 5,0 | 3,6 | complement component 1, q subcomponent, gamma polypeptide |
RN.10139 | 10,9 | 12,8 | 10,1 | chemokine (c-c motif) ligand 3 |
RN.16670 | 5,9 | 4,2 | 4,5 | basic leucine zipper transcription factor, atf-like (predicted) |
RN.6702 | 5,0 | 4,8 | 3,1 | complement component 1, q subcomponent, beta polypeptide |
RN.42962 | 4,3 | 6,8 | 6,2 | integrin beta 2 |
RN.33323 | 6,0 | 6,0 | 4,8 | fc receptor, igg, low affinity iib |
Complement and Coagulation Cascades | ||||
RN.81052 | 2,7 | 4,5 | 4,5 | complement component 4a |
RN.780 | 7,0 | 3,9 | 4,1 | alpha-2-macroglobulin |
RN.100285 | 7,7 | 9,9 | 8,3 | serine (or cysteine) peptidase inhibitor, clade g, member 1 |
RN.9772 | 4,4 | 3,6 | 2,5 | complement component 3a receptor 1 |
RN.6702 | 5,0 | 4,8 | 3,1 | complement component 1, q subcomponent, beta polypeptide |
RN.98333 | 4,2 | 4,6 | 4,0 | complement component 2 |
RN.21393 | 3,7 | 6,5 | 5,7 | coagulation factor x |
Cell Motility | ||||
RN.66513 | 5,8 | 7,2 | 5,8 | arachidonate 12-lipoxygenase (predicted) |
RN.6282 | 5,0 | 5,0 | 4,8 | insulin-like growth factor 1 |
RN.2090 | 3,7 | 3,4 | 2,7 | actin related protein 2/3 complex, subunit 1b |
RN.14655 | 9,6 | 5,6 | 4,1 | integrin alpha l |
RN.95169 | 3,2 | 3,7 | 3,0 | abi gene family, member 3 |
RN.101608 | 4,9 | 4,2 | 4,5 | lymphocyte specific 1 |
RN.10139 | 10,9 | 12,8 | 10,1 | chemokine (c-c motif) ligand 3 |
RN.49170 | 4,7 | 4,4 | 3,4 | suppression of tumorigenicity 14 |
RN.42962 | 4,3 | 6,8 | 6,2 | integrin beta 2 |
Apoptosis | ||||
RN.66513 | 5,8 | 7,2 | 5,8 | arachidonate 12-lipoxygenase (predicted) |
RN.6282 | 5,0 | 5,0 | 4,8 | insulin-like growth factor 1 |
RN.16195 | 3,7 | 4,0 | 3,2 | caspase 11 |
RN.16643 | 4,8 | 4,2 | 3,1 | fc receptor, igg, high affinity i |
RN.101608 | 4,9 | 4,2 | 4,5 | lymphocyte specific 1 |
RN.3176 | 4,2 | 4,7 | 3,8 | lymphocyte antigen 86 (predicted) |
RN.7110 | 6,0 | 4,9 | 4,2 | receptor-interacting serine-threonine kinase 3 |
RN.18985 | 4,0 | 5,0 | 3,3 | protein tyrosine phosphatase, non-receptor type 6 |
RN.42962 | 4,3 | 6,8 | 6,2 | integrin beta 2 |
RN.10089 | 4,7 | 4,2 | 3,8 | cyclin-dependent kinase inhibitor 1a |
RN.90166 | 3,4 | 3,7 | 3,2 | protein tyrosine phosphatase, receptor type, c |
RN.10250 | 4,6 | 2,7 | 3,2 | growth arrest and dna-damage-inducible 45 alpha |
Intracellular Signaling Cascade | ||||
RN.6282 | 5,0 | 5,0 | 4,8 | insulin-like growth factor 1 |
RN.68084 | 6,3 | 4,3 | 7,7 | b-cell leukemia/lymphoma 3 (predicted) |
RN.780 | 7,0 | 3,9 | 4,1 | alpha-2-macroglobulin |
RN.35286 | 3,4 | 4,0 | 2,9 | similar to ptpl1-associated rhogap 1 (predicted) |
RN.138976 | 3,3 | 3,6 | 2,9 | sh3-domain binding protein 2 |
RN.19450 | 19,4 | 25,9 | 18,5 | adenylate cyclase 7 |
RN.38575 | 3,2 | 3,8 | 3,5 | neutrophil cytosolic factor 1 |
RN.7110 | 6,0 | 4,9 | 4,2 | receptor-interacting serine-threonine kinase 3 |
RN.18985 | 4,0 | 5,0 | 3,3 | protein tyrosine phosphatase, non-receptor type 6 |
RN.11534 | 3,6 | 3,8 | 3,2 | tyro protein tyrosine kinase binding protein |
RN.10748 | 2,9 | 3,9 | 5,5 | cd4 antigen |
RN.48861 | 5,2 | 4,8 | 3,6 | vav 1 oncogene |
RN.40136 | 3,5 | 4,3 | 3,2 | transforming growth factor, beta 1 |